Zelnorm For Chronic Constipation Should Exclude Males And Seniors – Cmte.
Executive Summary
Novartis' Zelnorm should be approved for treatment of patients with chronic constipation who are under 65 years of age and female, FDA's Gastrointestinal Drugs Advisory Committee recommended July 14
You may also be interested in...
FDA Review Of Fertility Drug Use For Safety Signals To Use IMS Data
FDA's Office of Drug Safety is conducting a nationwide analysis of the use of fertility drugs as a basis for an evaluation of post-marketing safety issues with fertility treatments
FDA Review Of Fertility Drug Use For Safety Signals To Use IMS Data
FDA's Office of Drug Safety is conducting a nationwide analysis of the use of fertility drugs as a basis for an evaluation of post-marketing safety issues with fertility treatments
Novartis Plans Chronic Constipation Disease Ads Following Zelnorm Approval
Novartis plans to begin a patient-directed disease awareness campaign on chronic constipation in 2005